Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 58 | BSPED2018 | Next issue

46th Meeting of the British Society for Paediatric Endocrinology and Diabetes

Birmingham, UK
07 Nov 2018 - 09 Nov 2018

Card image cap
Birmingham, UK - 7-9 November 2018

ea0058p007 | Bone | BSPED2018

Impact of type 1 diabetes mellitus on skeletal integrity and strength assessed by HRpQCT

Devaraja Janani , Dimitri Paul , Jacques Richard , Paggiosi Margaret , Clark Carolyn , Bishop Nick

Introduction: Adults with Type 1 Diabetes Mellitus (T1DM) are at risk of premature osteoporosis and fractures. The onset of T1DM typically starts during childhood and adolescence thus the effects of diabetes on the skeleton may be established in this period. Studies in children primarily use DXA to evaluate the effects of T1DM on bone with conflicting results. We present the first study in children assessing the impact of T1DM on skeletal microstructure and strength, using HRp...

ea0058p008 | Bone | BSPED2018

Incidental morphological findings on bone age radiographs: their importance in clinical diagnosis

Stirling Heather , Ali Sana , Selmi Mariyah , Joshi Anuja , Helm Emma , Parsons Caron

Background: X-rays of the hand and wrist are routinely performed to evaluate bone age (BA) in children with endocrine and growth disorders. BA is used essentially to assess growth potential, but the BA x-ray can reveal additional morphological abnormalities. Incidental findings on the BA x-ray can aid clinical diagnosis and prompt appropriate further investigations to establish the childÂ’s final diagnosis.Methods: A 10-year retrospective review of 1...

ea0058p009 | Bone | BSPED2018

A case of persistent hypercalcaemia, following accidental denosumab administration

Paltoglou George , Brain Caroline , Amin Rakesh , Durani Sina , Rajamoorthy Vidhooshni , Esther Freeman , Braha Nirit , De Keyser Paul , Calder Alistair , Allgrove Jeremy

Introduction: Denosumab, a human monoclonal antibody that inhibits activation of osteoclasts provides sustained suppression of bone turnover in osteolytic bone disease. Denosumab has rarely been associated with late hypercalcaemia following therapeutic administration for bone tumours in children, bone metastases in adults and in children with Osteogenesis Imperfecta Type VI.Case report: A male child of Indian origin was referred for advice to GOSH from a...

ea0058p010 | Bone | BSPED2018

Changes in bone mineral density from age 10 to 30 years in individuals with cystic fibrosis

Bucknall Thomas , Bucknall Catrin , Parsons Camille , Ward Kate , Legg Julian , Davies Justin H

Background: Osteoporosis and increased fracture risk associated with cystic fibrosis (CF) are becoming more relevant with improved life expectancy in this disease. The evolution of CF-related bone disease remains unclear.Aims: To evaluate change in bone mineral density (BMD) in individuals with CF from age 10 to 30 y.Methods: Data from the UK CF Trust registry, which contains anonymised clinical information, was used to evaluate BM...

ea0058p011 | Bone | BSPED2018

Congenital hyperinsulism of infancy in a child with autosomal dominant hypocalcaemia type1 due to an activiting calcium sensing receptor mutation

Gevers Evelien , Martinez Ana Sastre , Shah Pratik

Introduction: Autosomal dominant hypocalcaemia (ADH) is caused by activating mutations of the calcium sensing receptor (CaSR). Symptomatology ranges from asymptomatic hypocalcaemia to paraesthesia, tetani, laringospasm and, seizures. This is the first report of congenital hyperinsulinism (CHI) in a child with ADH.Case report: A female infant, born at term from non-consanguineous parents, presented on D2 with persistent asymptomatic hypoglycaemia requirin...

ea0058p012 | Bone | BSPED2018

An unusual case of an infant presenting with Tetany and seizures secondary to phosphate supplementation

Gopalakrishna Nagapratheek , Kumar Kiran

Introduction: Hypocalcemia is a well known adverse reaction of phosphate supplements but rarely reported. We report a case of Infant presenting with hypocalcemic seizures after initiation of phosphate supplements.Clinical case: A baby Girl was born at 34+4 weeks gestation. She was admitted in NNU for preterm care. The admission was complicated by severe Gastroesophageal reflux disease(confirmed by PH impedance study), anemia and sepsis. She was discharge...